Boehringer's BIBF 1120 meets IPF endpoint

Boehringer Ingelheim GmbH (Ingelheim, Germany) said twice-daily 150 mg oral BIBF 1120 met the primary endpoint of significantly reducing the rate of forced vital capacity (FVC) decline from baseline t...